WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that biomarker data ...

Four key concepts are essential for understanding Clojure’s functional programming paradigm. Here’s how to apply what you ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Understand the cash flow statement for Replimune Group, Inc. (REPL), learn where the money comes from and how the company spends it.

A widely-adopted JavaScript library has been found carrying a critical vulnerability which could allow threat actors to execute malicious code, remotely.

Google has fixed a vulnerability in Chrome versions 141.0.7390.122/123 for Windows and macOS and 141.0.7390.122 for Linux. According to Google, the vulnerability is not yet being exploited in the wild ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...